Amyloidosis is caused by the deposition of amyloid substances due to various reasons,and when the heart is involved,it leads to cardiac amyloidosis(CA),which can even result in heart failure.Early diagnosis and accurate classification are crucial for the treatment of patients with these conditions.Nuclear imaging technique plays an important role in the diagnosis and classification of CA,particularly the use of 99Tcm-labeled bone imaging agents,which is particularly significant in diagnosing cardiac transthyretin amyloidosis.However,there is still a lack of mature and sensitive imaging methods for diagnosing light chain-type CA.The development of new amyloid-specific radiotracers,especially 18F-labeled PET molecular imaging agents,could address the shortcomings of the current bone imaging agents and aid in further classification of CA.These new agents could improve diagnostic accuracy,enable early detection,prognostic assessment,and therapeutic monitoring.This article reviews the current status and progress of nuclear imaging agents for cardiac amyloidosis in recent years.Although some tracers are still under research stage,their advantages are significant,and they are expected to play an important role in the diagnosis and treatment of cardiac amyloidosis,and further promote the development of more precise medical care.
维普
万方数据